FindTrial
Sign In

Demethylation therapy for juvenile myelomonocytic leukemia based on multiomics classification

Demethylation therapy for juvenile myelomonocytic leukemia based on multiomics classification

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037463
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile myelomonocytic leukaemia

Interventions

low risk:Watch and wait
intermediate risk:demethylation drug
high risk:Allogeneic hematopoietic stem cell transplantation combined with demethylation therapy

Sponsors

Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of JMML as defined by the 2016 WHO criteria; 2. Aged <=18 years; 3. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe organ dysfunction not caused by the disease; 2. Combined with other tumors (such as solid tumors) or hematopoietic diseases; 3. Prior hematopoietic stem cell transplantation or other intravenous chemotherapy.

Design outcomes

Primary

MeasureTime frame
1-year diseae-free survival rate;Response rate of demethylation therapy;—

Countries

China

Contacts

Public ContactChen Jing

Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine

chenjingscmc@hotmail.com+86 021-38626161-82030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026